基于靶向α核素治疗的纳米颗粒药物递送系统的研究进展  

Progress in nanoparticle-based drug delivery system for targeted alpha-particle therapy

作　　者：何雨珊 刘梦雅[1] 秦秀军[1] He Yushan;Liu Mengya;Qin Xiujun(Institute of Radiation and Environment Medicine,China Institute for Radiation Protection,Taiyuan 030006,China)

机构地区：[1]中国辐射防护研究院放射医学与环境医学研究所,太原030006

出　　处：《中华核医学与分子影像杂志》2024年第10期637-640,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：2023年度山西省基础研究计划(202303021212386,202303021222403)。

摘　　要：靶向α核素治疗是将α核素与配体结合,利用核素的射线能量和在组织中的射程集中照射病变组织,避免正常组织受损并获得预期治疗效果,现主要用于肿瘤治疗。靶向配体是能够将α核素运送至靶点精准杀伤肿瘤细胞的理想药物载体。近年来,基于α核素药物的靶向配体在纳米材料方面有了一定进展,改善了药物递送、脱靶效应等问题。该文总结了纳米颗粒药物递送系统的国外研究现状,以期为业内α核素药物递送研发提供参考。By binding alpha-particle to ligands,targeted alpha-particle therapy illuminates the diseased tissue,using the radiographic energy and the range in the tissues of nuclides,and avoids damage to normal tissue to obtain the expected therapeutic effect,which is mainly used for tumor treatment.Targeted ligands are ideal drug carriers to deliver alpha-particle to the target to kill tumor cells accurately.In recent years,there have been some progresses in the research ofα-radionuclide drug-based targeted ligands in nanomaterials,which have improved drug delivery and off-target effects.By summarizing the current research status,it is expected to provide reference for the development of alpha-particle drug delivery in the industry.

关 键 词：药物释放系统 纳米粒子 放射疗法 Α粒子 发展趋势 

分 类 号：R943[医药卫生—药剂学]